Clinical implications of pharmacogenomics for tardive dyskinesia.
about
Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines.Genetics of antipsychotic treatment emergent weight gain in schizophrenia.Pharmacogenetics of antipsychotics.Metoclopramide in the treatment of diabetic gastroparesis.Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence.Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.Lessons from pharmacogenetics and metoclopramide: toward the right dose of the right drug for the right patient.Pharmacogenetic considerations in the treatment of psychiatric disorders.Pharmacogenetics of tardive dyskinesia: an updated review of the literature.Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genes.Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions.Pharmacogenetics of antipsychotic treatment response and side effects.The catechol-O-methyl-transferase gene in tardive dyskinesia.DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia.Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia.Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients.Forthcoming ethical issues in biological psychiatry.Possible association between DBH 19 bp insertion/deletion polymorphism and clinical symptoms in schizophrenia with tardive dyskinesia.
P2860
Q33232404-42628D84-695D-44CB-A136-BB8894589FDAQ33257886-14DA12CF-CB21-4552-94C0-1FA3F9E927B7Q33836837-F4435048-B060-45E2-8C8E-02CD89D33A58Q34521600-A011E0C2-42F3-437A-B4D5-D86AEAB6455BQ34625174-F166B9F9-FADA-45E1-A052-4D37763BDD93Q34660856-5285BF37-F41B-4D8E-AE64-944D330F962BQ35693061-59B77C83-AB93-4004-8A79-E8F7DF6C6787Q36028732-100B16C1-7943-4959-9D8E-ACFCB213D9D1Q37681573-DFC4454D-404C-4B04-B47D-6D303D915D21Q38911685-5A364AC7-F30E-4A6B-A21A-1CBCAB95968AQ39410894-E58A1BA4-DED0-4410-9E50-CE50370BE3EFQ40136199-152C033A-F7EE-4A33-82EE-A270AF260E26Q40663726-D6943FA1-8389-4215-BD91-C2C62152AF5CQ43002336-157CAC3F-07FA-4890-B430-6784FC10AFBDQ44582314-4E113FC2-8B58-4E28-9C16-4F6CB14AA2F9Q45185178-2B0270EB-AE38-4CDF-9212-FCF4382B4EDEQ46422249-70717A69-95CC-4333-938C-DABA57766AAEQ48767794-335EB654-CADD-489C-B63F-71E26E0CA0EBQ50616840-3A395192-EA46-432D-A305-478D95B13AD8
P2860
Clinical implications of pharmacogenomics for tardive dyskinesia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clinical implications of pharmacogenomics for tardive dyskinesia.
@ast
Clinical implications of pharmacogenomics for tardive dyskinesia.
@en
type
label
Clinical implications of pharmacogenomics for tardive dyskinesia.
@ast
Clinical implications of pharmacogenomics for tardive dyskinesia.
@en
prefLabel
Clinical implications of pharmacogenomics for tardive dyskinesia.
@ast
Clinical implications of pharmacogenomics for tardive dyskinesia.
@en
P2093
P2860
P356
P1476
Clinical implications of pharmacogenomics for tardive dyskinesia.
@en
P2093
P2860
P2888
P356
10.1038/SJ.TPJ.6500233
P577
2004-01-01T00:00:00Z